ClinicalTrials.gg
Not yet recruitingNCT07416032Updated Feb 17, 2026

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia

An Early Phase 1 interventional study of QT-019C in Immune Thrombocytopenia (ITP), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 84 open to participants now, 94 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
131st of 169
27 · median 60
Started
2026
with 20 others
Phase 1
21 of 187
12 open now
Primary completion
2028-06
later than 84 of 93 live
Registered
174th of 187
by date

Among the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 131st largest by planned enrollment of the 169 interventional ones that give a count, is one of 21 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 84 of the 93 other live ones, and was the 174th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

84 of the 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia.

Read the detailed description

This study is a single-arm, open-label clinical trial aimed at evaluating the safety, tolerability, and efficacy of QT-019C in patients with refractory primary ITP, and obtaining pharmacokinetic(PK) and pharmacodynamic(PD) data. The study comprises two phases: dose escalation and dose expansion, and plans to recruit 10 to 27 participants. Dose escalation will follow a 3 + 3 design, and 10 to 21 participants will be included in this phase. Four dose groups (Group A, Group B, Group C, and Group D) will be set up. Participants who sign the informed consent forms and have been screened by inclusion/exclusion criteria will undergo leukapheresis, lymphodepletion pre-treatment, and a single infusion of QT-019C. Participants will undergo regular checks to evaluate the safety and tolerability of the treatment, along with data on PK, PD, and preliminary efficacy. After the last subject in each dose group has completed the dose-limiting toxicity (DLT) assessment window of 28 days after a single dose, enrollment and treatment for the next dose group may be initiated after the Safety Review Committee (SRC) agrees to enter the next dose group based on clinical safety data assessment. After the dose escalation is completed, the SRC will determine whether to conclude the study or select a dose level or dose range as the recommended dose (RD) for a dose expansion study based on the conditions of the dose escalation phase. 6 participants will be included in this phase for further assessment of QT-019C's safety and early efficacy. All participants will complete a follow-up up to 24 months.

03

Conditions studied

  • Immune Thrombocytopenia (ITP)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Participants aged ≥18 years and ≤75 years, regardless of gender.
  • 2. Clinically diagnosed with primary immune thrombocytopenia for no less than 6 months, with counts \< 30×10\^9/L in two separate tests conducted within 15 days before the initiation of study treatment, with at least 7 days between the tests.
  • 3. Presence of any anti-platelet glycoprotein autoantibody (GPIb/GPIX/GPIIb/GPIIIa/GMP140) positive.
  • 4. Meet the criteria for ITP: previously received and/or second-line ITP treatment (first-line treatment includes or immunoglobulins; second-line treatment includes thrombopoietin receptor agonists (such as eltrombopag, romiplostim), rituximab, splenectomy, etc.), but ineffective (post-treatment platelet count \<30×10\^9/L, or platelet count increase less than twice the baseline value, or presence of bleeding), or relapse after initial response or difficult to maintain after discontinuation.
  • 5. Important organ functions are basically normal during the selection period:

    1. Echocardiogram indicates >50%, shows no significant abnormalities;
    2. (CrCl) (Cockcroft-Gault formula) >30 mL/min;
    3. (ALT) and aspartate aminotransferase (AST) \<3.0x the (ULN);
    4. Total (TBIL) and alkaline phosphatase (AKP or ALP) \<2.0x ULN (Gilbert's syndrome \<3.0x UN);
    5. Absolute lymphocyte count (ALC) >0.5x10\^9; (ANC) >1x10\^9; (Hb) >60g;
    6. Oxygen saturation >92%.
  • 6. Female participants of and male participants who are partners of women of childbearing age must use medically accepted measures or abstain for at least 12 months during and after the study treatment; female participants of childbearing age must have a negative serum HCG test within 7 days before study enrollment and must not be breastfeeding.
  • 7. Volunteer to participate in this clinical study, sign , demonstrate good compliance, and cooperate with follow-up.

Exclusion criteria

Exclusion Criteria:

  • 1. Secondary thrombocytopenia caused by myelodysplastic syndromes, splenic hyperfunction, diseases, early aplastic anemia, atypical aplastic anemia, and thrombotic thrombocytopenic purpura, among other causes.
  • 2. Bone marrow examination results during the screening phase indicate bone marrow fibrosis MF>2 (European expert consensus scoring criteria for bone marrow fibrosis, Thiele et al., 2005) or the bone marrow examination suggests the presence of other primary conditions causing thrombocytopenia aside from ITP.
  • 3. History of any of the following heart diseases:

    1. class II or IV congestive heart failure;
    2. Myocardial infarction within 6 months before signing the ICF, or having undergone coronary artery bypass grafting (CABG) or coronary artery stent implantation;
    3. ventricular arrhythmias or a history of unexplained syncope (excluding cases caused by vasovagal or dehydration);
    4. History of severe non-ischemic cardiomyopathy.
  • 4. Patients who have previously received gene-modified cell therapies such as TCR-T, CAR-T, CAR-NK, etc.
  • 5. Patients who are positive for surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA levels exceeding the upper limit of detection; those who are positive for virus (HCV) antibodies and have positive peripheral blood HCV RNA; those who are positive for (HIV) antibodies; and those who test positive for syphilis.
  • 6. Subjects who have received the following drug treatments before the start of the study will be excluded:

    1. B-cell and antibody-secreting cell (ASC) depletion therapy:

      i. Subjects who have received anti-CD20 monoclonal antibody treatment (such as rituximab) within 3 months before screening will be excluded. If such treatment occurred more than 3 months but not more than 6 months before screening, and if the absolute count of peripheral blood CD19⁺ B cells is above the lower limit of normal (as determined by local or central laboratory), then enrollment may be allowed after confirmation by the investigator and the medical director of the sponsor (or designated representative).

      ii. Subjects who have previously received simultaneous CD19-targeting and BCMA-targeting treatments will be excluded. Subjects who have received CD19-targeting or BCMA-targeting treatment (either one) within 6 months before screening will also be excluded. If such treatment occurred more than 6 months before screening, and if the absolute count of peripheral blood CD19⁺ B cells is above the lower limit of normal (as determined by local or central laboratory), then enrollment may be allowed after confirmation by the investigator and the medical director of the sponsor (or designated representative).

      iii. Subjects who have used or adjusted the dosage of BTK and SyK inhibitors within 2 weeks before screening should be excluded. If the dosage has been stable for ≥ 2 weeks before screening, then they may be included.

    2. Subjects who have used or adjusted TPO-RA treatment within 2 weeks before screening should be excluded. However, those who have been on a stable dose for more than 2 weeks before screening may continue treatment.
    3. Subjects who have used IVIG or undergone plasma exchange within 4 weeks before screening should be excluded.
    4. Subjects who have used (such as cyclophosphamide, mycophenolate mofetil (MMF), azathioprine, and methotrexate) within 2 weeks before lymphocyte depletion will be excluded.
  • 7. Subjects who have used prednisone > 10 mg/day or have had dosage adjustments within 2 weeks before screening. Oral treatment equivalent to ≤ 10 mg/day of prednisone is acceptable at enrollment, provided the dosage has been stable for at least 2 weeks before enrollment.
  • 8. Subjects with a history of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before screening, or who currently require anticoagulation therapy.
  • 9. Subjects with a history of any organ system (except well-prognosed tumors such as localized basal cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, follicular or papillary thyroid carcinoma, etc.) within the past 5 years, regardless of whether there is evidence of local recurrence or ; or known concomitant life-threatening diseases.
  • 10. Subjects with any active infection or any infection requiring systemic anti-infective treatment within 30 days before screening.
  • 11. Any known factors, diseases, or clinically relevant medical conditions or surgical situations that the investigator believes may place the subjects at risk, interfere with treatment compliance, study implementation, or outcomes.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    QT-019C (Universal allogeneic anti-CD19/BCMA CAR T-cells)

    The study comprises two phases: dose escalation and dose expansion. Dose escalation will follow a 3 + 3 design, and 10 to 21 participants will be included in this phase. Four dose groups (Group A, Group B, Group C, and Group D) will be set up, and the administered dose of QT-019C starts at 1×10\^6 cells/kg (Group A). Participants will undergo regular checks to evaluate the safety and tolerability of the treatment, along with data on PK, PD, and preliminary efficacy. After the completion of the dose escalation, the Safety Review Committee (SRC) will determine whether to conclude the study or select a dose level or range as the recommended dose (RD) for dose expansion research. 6 participants will be included in this phase for further assessment of QT-019C's safety and early efficacy. All participants will complete a follow-up up to 24 months.

    Drug: QT-019C

Interventions

  • QT-019C is a chimeric antigen receptor T-cell (CAR-T) therapy targeting both BCMA and CD19. Participants will undergo leukocyte separation to collect monocytes for the manufacturing of QT-019C. Before infusion(Day -5), participants receive lymphodepletion with cyclophosphamide for 3 days and undergo a safety check on Day -1. Eligible participants will receive an intravenous infusion of QT-019C on Day 0. The period from the infusion until Day 28 will be the dose-limiting toxicity (DLT) observation period, during which the occurrence of DLT events and other adverse events will be closely monitored, as well as changes in other indicators (such as pharmacokinetics, pharmacodynamics, and preliminary efficacy). Participants are monitored for safety and efficacy for up to 24 months.

    Also known as: Universal allogeneic anti-CD19/BCMA CAR T-cells

06

What researchers measure

Primary outcomes

  1. The number and severity of dose-limiting toxicity (DLT)events

    DLT will be graded according to the NCl Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, andthe ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with lmmune Effector Cells.

    Time frame: Within 28 Days After QT-019C infusion

  2. The total number, incidence, and severity of Adverse Events(AEs)

    The total number, incidence, and severity of Adverse Events(AEs)

    Time frame: Within 28 Days After QT-019C infusion

Secondary outcomes

  1. Clinical response of relapsed/refractory ITP

    Complete response (CR) rate or Response (R) rate of administering QT-019C in the treatment of refractory ITP. CR is defined as a platelet count ≥100×10⁹/L. PR is defined as a platelet count ≥30×10⁹/L, with an increase of at least two times from baseline, and no active bleeding.

    Time frame: Up to 24 Months After QT-019C Infusion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jun 2028, 28 months later.

Of 27 phase 1 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 17, 2026
StartEst.
Feb 20, 2026
Primary completionEst.
Jun 20, 2028
CompletionEst.
Mar 1, 2029
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07416032
Collaborators
Shanghai Xiniao Biotech Co., Ltd.
Responsible party
MEI HENG (Professor, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Feb 17, 2026
Start date
Feb 20, 2026 (estimated)
Primary completion
Jun 20, 2028 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

Heng Mei, Ph.D&M.D
Contact
hmei@hust.cdu.cn
027-8572600
Jinhui Shu, Ph.D
Contact
sjh18326016087@163.com
18326016087
Heng Mei, Ph.D&M.D
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QT-019C

Start the discussion